ASMB - NASDAQ
Assembly Biosciences, Inc.
$24.11
-1.6%Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
At a Glance
Live Snapshotasmb
Total Assets
Last Annual Value
257.59M
3-Year CAGR
36%
5-Year CAGR
-2%
10-Year CAGR
7%
Assembly Biosciences, Inc. Competitors Analysis of Total Assets
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Assembly Biosciences, Inc. NASDAQ:ASMB | 257.59M | 23.5% | 6.2% | 10.1% | |
 Arcturus Therapeutics Holdings Inc. NASDAQ:ARCT | 271.15M | -14.2% | -7.1% | 18.1% | |
 Enanta Pharmaceuticals, Inc. NASDAQ:ENTA | 280.73M | -15.3% | -8.6% | -0.0% | |
 Foghorn Therapeutics Inc. NASDAQ:FHTX | 198.10M | -11.5% | -17.5% | N/A | |
 Tenaya Therapeutics, Inc. NASDAQ:TNYA | 146.92M | -4.8% | -14.2% | N/A | |
 Sagimet Biosciences Inc. NASDAQ:SGMT | 116.48M | 6.4% | 14.6% | N/A | |
 Immuneering Corporation NASDAQ:IMRX | 231.99M | 31.3% | 6.8% | N/A | |
 Neonc Technologies Holdings, Inc. NASDAQ:NTHI | 2.82M | 30.7% | 144.2% | N/A | |
 Cassava Sciences, Inc. NASDAQ:SAVA | 118.36M | -7.9% | -15.0% | 19.9% | |
 Sangamo Therapeutics, Inc. NASDAQ:SGMO | 59.74M | -28.8% | -39.2% | -9.3% | |
 SELLAS Life Sciences Group, Inc. NASDAQ:SLS | 78.34M | 132.7% | 24.3% | 1.8% |
Assembly Biosciences, Inc. Fair Value Envelope
Related Guides
Continue your ASMB research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.